{"drugs":["Pasireotide","Signifor LAR"],"mono":{"0":{"id":"931318-s-0","title":"Generic Names","mono":"Pasireotide"},"1":{"id":"931318-s-1","title":"Dosing and Indications","sub":[{"id":"931318-s-1-4","title":"Adult Dosing","mono":"<b>Acromegaly, In patients with an inadequate response to surgery or who are not candidates for surgery:<\/b> Initial: 40 mg IM once every 4 weeks; may increase to 60 mg IM once every 4 weeks if growth hormone or adjusted insulin-like growth factor-1 levels have not normalized after 3 months of treatment; MAX dose, 60 mg IM once every 4 weeks "},{"id":"931318-s-1-5","title":"Pediatric Dosing","mono":"Efficacy and safety not established in pediatric patients "},{"id":"931318-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> No dose adjustment necessary<\/li><li><b>Hepatic impairment, mild (Child-Pugh A):<\/b> No dose adjustment necessary<\/li><li><b>Hepatic impairment, moderate (Child-Pugh B):<\/b> Reduce initial dose to 20 mg IM once every 4 weeks; max dose, 40 mg IM once every 4 weeks<\/li><li><b>Hepatic impairment, severe (Child-Pugh C):<\/b> Avoid use<\/li><li><b>Geriatric:<\/b> Initiate at low end of dosing range<\/li><li><b>Adverse reactions or overresponse to treatment (insulin-like growth factor-1 levels below lower limit of normal):<\/b> Decrease dose temporarily or permanently in decrements of 20 mg<\/li><\/ul>"},{"id":"931318-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Acromegaly, In patients with an inadequate response to surgery or who are not candidates for surgery<br\/>"}]},"3":{"id":"931318-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931318-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"931318-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Bradycardia has been reported; monitoring recommended for those with cardiac disease or risk factors for bradycardia and dose adjustment of drugs that slow the heart rate may be necessary<\/li><li>-- QT prolongation has been reported; use cautiously in patients with congenital QT prolongation, uncontrolled or significant cardiac disease, concomitant use of QT prolonging medications, hypokalemia, or hypomagnesemia; monitoring recommended and correct electrolyte abnormalities prior to initiation<\/li><li>Endocrine and Metabolic:<\/li><li>-- Hyperglycemia may occur and monitoring is recommended; initiation or adjustment of antidiabetic medications and\/or dose adjustment or discontinuation of pasireotide may be necessary<\/li><li>-- Optimize treatment of poorly controlled diabetes prior to initiation<\/li><li>-- Pituitary hormone suppression may occur; monitoring recommended<\/li><li>Gastrointestinal:<\/li><li>-- Cholelithiasis has been reported; monitoring recommended<\/li><li>Hepatic:<\/li><li>-- Increases in liver enzymes have been reported; monitoring recommended and discontinuation may be necessary<\/li><li>-- Moderate hepatic impairment; dose adjustment recommended<\/li><li>-- Avoid use in patients with severe hepatic impairment<\/li><\/ul>"},{"id":"931318-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"931318-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931318-s-4","title":"Drug Interactions","sub":[{"id":"931318-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"931318-s-4-14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Albiglutide (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Dulaglutide (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Empagliflozin (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Exenatide (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Insulin (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Bovine (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Linagliptin (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lixisenatide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perflutren Protein Type A Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Pipamperone (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Repaglinide (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><\/ul>"}]},"5":{"id":"931318-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>High hemoglobin A1c level (6%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (Treatment-experienced, 16% to 19%; treatment-naive, 39%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval (4%), Sinus bradycardia (10%)<\/li><li><b>Endocrine metabolic:<\/b>Diabetes mellitus (21% to 31%), Hyperglycemia (29% to 33%)<\/li><\/ul>"},"6":{"id":"931318-s-6","title":"Drug Name Info","sub":{"0":{"id":"931318-s-6-17","title":"US Trade Names","mono":"Signifor LAR<br\/>"},"2":{"id":"931318-s-6-19","title":"Class","mono":"Somatostatin (class)<br\/>"},"3":{"id":"931318-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931318-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931318-s-7","title":"Mechanism Of Action","mono":"Pasireotide is a somatostatin analog formulated for IM use. Pharmacological activity occurs via binding to somatostatin receptors that are present in various tissues under normal physiological conditions and are expressed in neuroendocrine tumors.<br\/>"},"8":{"id":"931318-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"931318-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 88%<\/li><li>Vd: Greater than 100 L<\/li><\/ul>"},"2":{"id":"931318-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: Predominant<\/li><li>CYP450 levels may decrease due to suppression of growth hormone secretion<\/li><\/ul>"},"3":{"id":"931318-s-8-26","title":"Excretion","mono":"<ul><li>Renal: Minor, mostly unchanged<\/li><li>Total body clearance: 4.5 to 8.5 L\/hr<\/li><\/ul>"}}},"9":{"id":"931318-s-9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>Allow injection kit to stand at room temperature for at least 30 minutes but not longer than 24 hours prior to reconstitution; may re-refrigerate kit if necessary<\/li><li>Shake vial moderately in a horizontal direction for at least 30 seconds after adding the provided diluent; continue shaking for 30 more seconds if powder is not completely suspended; may gently shake syringe just prior to administration to prevent sedimentation<\/li><li>Administer the entire reconstituted volume immediately after reconstitution as an IM injection into the left or right gluteus at a 90 degree angle; do not give IV<\/li><li>Missed doses may be given for up to 14 days prior to the next scheduled dose<\/li><\/ul>"},"10":{"id":"931318-s-10","title":"Monitoring","mono":"<ul><li>Growth hormone (GH) and (sex adjusted) insulin growth factor 1 (IGF-1); 3 months after initiation<\/li><li>Improvement in signs and symptoms of acromegaly may indicate efficacy<\/li><li>Fasting plasma glucose and hemoglobin A1c; at baseline<\/li><li>Blood glucose; every week for the first 3 months of therapy, for the first 4 to 6 weeks after dose increases, and periodically thereafter, including after treatment discontinuation if indicated<\/li><li>Potassium and magnesium; at baseline and periodically during therapy.<\/li><li>Liver function tests; at baseline, 2 to 3 weeks after treatment initiation, then monthly for 3 months, and as clinically indicated thereafter<\/li><li>Pituitary function (eg, thyroid, adrenal, gonadal); at baseline and periodically during treatment as clinically appropriate<\/li><li>Signs and symptoms of bradycardia, in patients with cardiac disease or risk factors for bradycardia (eg, high-grade heart block, history of clinically significant bradycardia, or concomitant use of drugs that may cause bradycardia)<\/li><li>ECG; at baseline<\/li><li>Effect on the QTc interval, in patients with risk factors (eg, congenital long QT prolongation, uncontrolled or significant cardiac disease, on antiarrhythmic therapy or other drugs that prolong the QT interval, with hypokalemia or hypomagnesemia); at 21 days after first injection<\/li><li>Signs and symptoms of cholelithiasis; periodically<\/li><li>Signs and symptoms of adrenal insufficiency<\/li><\/ul>"},"11":{"id":"931318-s-11","title":"How Supplied","mono":"<b>Signifor LAR<\/b><br\/>Intramuscular Powder for Suspension: 20 MG, 40 MG, 60 MG<br\/>"},"12":{"id":"931318-s-12","title":"Toxicology","sub":[{"id":"931318-s-12-31","title":"Clinical Effects","mono":"<b>OCTREOTIDE AND RELATED AGENTS<\/b><br\/>OVERDOSE: Overdose data are limited with these agents; hypoglycemia, flushing, dizziness and nausea have been reported. ADVERSE EFFECTS: Gastrointestinal adverse effects (eg; anorexia, nausea, vomiting, diarrhea and steatorrhea, constipation, abdominal discomfort, and flatulence) are the most common effects.  Gallstones, hypoglycemia and hyperglycemia, dizziness, pancreatitis, hypothyroidism, sinus bradycardia, conduction abnormalities, dysrhythmias, thrombocytopenia, and hepatitis have also been reported.<br\/>"},{"id":"931318-s-12-32","title":"Treatment","mono":"<b>OCTREOTIDE AND RELATED AGENTS <\/b><br\/><ul><li>Decontamination: Significant toxicity is not anticipated after ingestion because of limited  bioavailability.  Treatment is symptomatic and supportive.  Consider activated charcoal only after very large ingestions.<\/li><li>Hyperglycemia: If significant hyperglycemia occurs, careful blood glucose monitoring and insulin therapy might be required.<\/li><li>Hypoglycemia: Give dextrose if symptomatic or BS &lt;60 mg\/dL. Dose - Adult 50 mL of 50% dextrose IV push; Child 0.5 to 1 g\/kg (2-4 mL\/kg) of 25% dextrose IV push. Feed oral carbohydrates. If recurrent hypoglycemia develops, repeat dextrose bolus and follow with an infusion of 10% dextrose; titrate to a BS of 100 mg\/dL.<\/li><li>Bradycardia: ATROPINE: ADULT DOSE: BRADYCARDIA: 0.5 to 1 mg IV every 5 min. ASYSTOLE: 1 mg IV every 5 min.  Maximum total dose 3 mg or 0.04 mg\/kg.  Minimum single dose 0.5 mg. PEDIATRIC DOSE: 0.02 mg\/kg IV repeat every 5 min, minimum single dose 0.1 mg; maximum single dose child 0.5 mg, adolescent 1 mg; maximum total dose 1 mg child, 2 mg adolescent.<\/li><li>Monitoring of patient: Vital signs, liver enzyme levels, blood glucose level, electrolytes and fluid status, ECG, and continuous cardiac monitoring in symptomatic patients.<\/li><\/ul>"},{"id":"931318-s-12-33","title":"Range of Toxicity","mono":"<b>OCTREOTIDE AND RELATED AGENTS<\/b><br\/>A minimum toxic dose has not been established has not been established for these agents. Overdoses of octreotide up to 120,000 mcg infused over 8 hours have been well tolerated.  Octreotide doses of 2.5 mg (2500 mcg) subcutaneously have caused hypoglycemia, flushing, dizziness, and nausea.<br\/>"}]},"13":{"id":"931318-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include diarrhea, abdominal pain, abdominal distension, headache, alopecia, and nasopharyngitis.<\/li><li>Instruct patient to report signs or symptoms of hyperglycemia (eg, excessive thirst, frequent urination, increased appetite with weight loss, or fatigue).<\/li><li>Advise diabetic patients to monitor for signs and symptoms of hyper- or hypoglycemia and to report difficulties with glycemic control.<\/li><li>Instruct patients to report signs or symptoms of bradycardia or QT-interval prolongation (dizziness, weakness, fainting).<\/li><li>Advise patient to report symptoms of cholelithiasis (sudden pain in upper right abdomen, in right shoulder, or in between shoulder blades; yellowing of skin or eyes; fever with chills; nausea).<\/li><li>Instruct patient to report signs or symptoms of pituitary hormone deficiency (nausea, vomiting, tiredness, dizziness, low blood glucose levels, loss of appetite, weight loss).<\/li><\/ul>"}}}